tabl
list
kinas
demonstr
phosphoryl
viral
protein
number
medic
relev
virus
tabl
includ
virus
encod
protein
phosphoryl
isol
experiment
system
singl
identifi
kinas
although
evid
phosphorylationkinas
predict
data
kinas
inhibitor
data
also
use
tabl
includ
viral
protein
substrat
experiment
phosphoryl
purifi
andor
isol
kinas
virus
list
protein
phosphoryl
unknown
kinas
tabl
viral
protein
shown
phosphoryl
biochem
data
yet
identifi
kinas
respons
tabl
repres
kinas
found
phosphoryl
viral
protein
demonstr
extens
role
phosphoryl
play
medic
relev
viral
infect
inclus
publish
literatur
viral
phosphoryl
event
tabl
found
pubm
literatur
search
use
search
term
specif
viru
kinas
andor
specif
viru
phosphoryl
specif
phosphoryl
site
viral
protein
identifi
mutat
analys
necessari
determin
potenti
phenotyp
effect
specif
phosphoryl
exampl
protein
contain
late
domain
involv
viru
bud
determin
phosphoprotein
phosphoryl
multipl
kinas
analysi
identifi
specif
phosphosit
phosphoryl
vitro
vivo
mapk
mutat
alanin
thu
block
phosphoryl
site
within
viru
mutant
show
reduc
infect
well
defect
viral
particl
matur
bud
work
necessari
determin
precis
exactli
phosphoryl
lead
observ
effect
viru
exampl
highlight
abil
phosphoryl
specif
site
viral
protein
impact
viral
life
cycl
caveat
perform
mutat
analys
import
ensur
mutant
protein
stabli
express
similar
level
protein
clearli
associ
phenotyp
effect
absenc
specif
phosphoryl
number
case
multipl
kinas
abl
phosphoryl
viral
protein
exampl
multipl
kinas
phosphoryl
human
adenoviru
rev
protein
abl
phosphoryl
ckii
mapk
vitro
number
kinas
includ
cki
ckii
phosphoryl
hcv
protein
contribut
hyperphosphoryl
form
although
specif
case
cki
ckii
phosphoryl
differ
site
within
although
phosphoryl
may
involv
transit
viral
protein
genom
replic
particl
assembl
site
distinct
although
aforement
vitro
data
help
preliminari
identif
kinas
vivo
experi
must
also
perform
determin
multipl
kinas
fact
phosphoryl
viral
protein
infect
cell
util
multipl
kinas
phosphoryl
viral
protein
viru
could
abil
expand
host
cellular
tropism
infect
differ
speci
cell
type
vari
kinas
profil
addit
kinas
redund
provid
multipl
opportun
viral
protein
phosphoryl
ensur
chanc
phosphoryl
protein
induc
pathogen
effect
cell
exampl
kinas
redund
exist
number
virus
includ
poxvirus
ebola
viru
vaccinia
viru
phosphoryl
member
src
abl
kinas
famili
kinas
involv
viral
particl
releas
inhibit
either
src
abl
famili
block
viral
releas
inhibit
kinas
famili
strongli
inhibit
releas
viral
particl
cell
cultur
exampl
kinas
redund
illustr
presenc
one
kinas
famili
kinas
may
suffici
induc
viru
pathogen
effect
even
absenc
kinas
util
viru
kinas
redund
must
also
consid
design
use
kinas
inhibitor
inhibitor
necessarili
entir
specif
one
kinas
kinas
famili
exampl
sprycel
act
src
abl
cellular
kinas
famili
profound
effect
cell
cultur
inhibitor
affect
abl
mous
though
less
specif
inhibit
may
help
discuss
later
number
viral
protein
found
phosphoryl
form
kinas
respons
yet
identifi
howev
import
phosphoryl
viral
life
cycl
investig
even
without
ident
kinas
rubella
viru
capsid
protein
instanc
phosphoryl
variou
site
unknown
kinas
phosphoryl
necessari
optim
viral
replic
number
cellular
kinas
appear
repeatedli
tabl
phosphoryl
protein
mani
differ
virus
exampl
ckii
shown
phosphoryl
protein
nearli
virus
list
cdk
also
util
number
virus
use
cdk
virus
understand
kinas
regul
state
cellular
growth
replic
would
seem
obviou
target
viral
manipul
tabl
howev
base
tissu
data
variabl
express
kinas
differ
tissu
could
affect
kinas
phosphoryl
protein
differ
virus
depend
tissu
infect
particular
viru
systemat
evalu
cellular
kinas
central
differ
viral
life
cycl
preponder
ckii
exampl
could
due
eas
demonstr
phosphoryl
viral
protein
ckii
oppos
ckii
import
viral
life
cycl
cellular
kinas
addit
cellular
kinas
phosphoryl
viral
protein
virus
encod
kinas
first
describ
bishop
varmu
viral
encod
kinas
may
phosphoryl
cellular
substrat
may
impact
cellular
protein
function
activ
viral
kinas
may
also
phosphoryl
viral
protein
andor
autophosphoryl
potenti
affect
viral
replic
product
within
cell
protein
kinas
abl
phosphoryl
number
viral
protein
includ
epstein
barr
nuclear
antigen
transcript
regul
hyperphosphoryl
mitosi
viru
latent
phase
viral
kinas
also
phosphoryl
manner
similar
cellular
kinas
lytic
phase
hyperphosphoryl
inhibit
normal
abil
transactiv
ebv
promot
regul
promot
via
phosphoryl
may
induc
continu
ebv
lytic
replic
cycl
although
phosphoryl
may
effect
viral
life
cycl
use
investig
role
specif
phosphoryl
fulli
understand
role
viral
protein
infect
cell
viral
kinas
may
also
autophosphoryl
autophosphoryl
cellular
kinas
occur
intermolecularli
intramolecularli
autophosphoryl
posit
neg
regul
cellular
kinas
catalyt
activ
potenti
alter
enzym
conform
phosphoryl
cellular
kinas
also
influenc
interact
protein
exampl
tyrosin
phosphoryl
specif
residu
within
kinas
requir
src
interact
protein
domain
tabl
rotaviru
hcmv
ebv
display
abil
autophosphoryl
although
full
effect
autophosphoryl
protein
activ
remain
investig
review
michel
merten
hcmv
autophosphoryl
conflict
data
regard
role
autophosphoryl
abil
phosphoryl
interact
protein
definit
known
whether
autophosphoryl
viral
kinas
induc
effect
regul
catalyt
activ
recruit
protein
interact
autophosphoryl
cellular
kinas
evid
compar
autophosphoryl
specif
site
homolog
cellular
viral
rou
sarcoma
viru
src
kinas
suggest
effect
specif
autophosphoryl
could
differ
even
relat
cellular
viral
kinas
studi
necessari
determin
autophosphoryl
viral
kinas
affect
protein
activ
structur
function
mani
kinas
character
recognit
motif
substrat
sequenc
phosphoryl
effici
particular
kinas
number
program
netphosk
scansit
develop
predict
phosphoryl
site
kinas
involv
basi
substrat
sequenc
although
use
search
engin
account
factor
cellular
local
signal
distant
kinas
substrat
site
might
sequest
otherwis
perfectli
good
substrat
away
kinas
research
catalog
tabl
aid
bioinformat
queri
tri
identifi
specif
phosphoryl
site
within
viral
protein
refer
list
tabl
experiment
data
support
phosphoryl
viral
protein
occur
well
great
deal
research
perform
identifi
cellular
substrat
kinas
worth
note
variat
amino
acid
sequenc
kinas
recognit
site
cellular
viral
substrat
still
allow
phosphoryl
viral
substrat
number
viral
substrat
phosphoryl
site
match
known
kinas
recognit
motif
exampl
hepat
c
viru
phosphoprotein
phosphoryl
vitro
cki
site
peptid
correspond
region
phosphoryl
effici
previous
phosphoryl
cki
phosphoryl
fit
canon
cki
recognit
site
expect
phosphoryl
residu
posit
variat
cki
recognit
site
note
literatur
may
depend
tertiari
structur
well
primari
amino
acid
sequenc
howev
viral
amino
acid
sequenc
differ
canon
kinas
recognit
site
may
impact
abil
current
program
predict
phosphoryl
specif
kinas
recognit
site
eichwald
et
al
determin
cki
capabl
phosphoryl
rotaviru
residu
lack
phosphoryl
residu
posit
string
three
four
acid
residu
phosphoryl
site
deviat
ideal
cki
recognit
site
neither
netphosk
scansit
program
recogn
potenti
phosphoryl
site
let
alon
site
abl
phosphoryl
cki
likewis
vaccinia
viru
protein
abl
phosphoryl
src
abl
tyrosin
kinas
howev
site
sit
within
canon
abl
kinas
recognit
site
lack
prolin
phenylalanin
posit
netphosk
scansit
predict
src
would
phosphoryl
anoth
exampl
kinas
recognit
site
variat
among
relat
virus
protein
kinas
g
pkg
phosphoryl
denv
protein
yfv
wnv
two
site
differ
substanti
canon
pkg
substrat
sequenc
flavivir
pkg
site
addit
differ
clear
motif
identifi
viral
substrat
figur
curious
denv
yfv
site
phosphoryl
pkg
within
motif
netphosk
analysi
predict
phosphoryl
denv
correctli
predict
pkg
phosphoryl
yfv
possibl
kinas
may
bind
substrat
site
distant
recognit
motif
phosphoryl
occur
distant
bind
site
may
import
phosphoryl
substrat
specif
kinas
wherea
scansit
recognit
potenti
kinas
recognit
motif
base
experi
identifi
optim
sequenc
surround
phosphoryl
site
within
peptid
substrat
librari
netphosk
neural
program
thu
netphosk
criteria
identifi
phosphoryl
site
kinas
respons
phosphoryl
easili
defin
programm
user
despit
variat
known
recognit
sequenc
andor
phosphoryl
predict
analys
biochem
cell
cultur
data
suggest
site
discuss
earlier
phosphoryl
kinas
question
thu
although
program
provid
good
start
point
studi
phosphoryl
viral
protein
one
must
use
caution
predict
phosphoryl
pattern
kinas
involv
phosphoryl
viral
substrat
substanti
differ
actual
predict
phosphorylationskinas
detect
specif
phosphoryl
becom
easier
recent
year
advanc
phosphopeptid
enrich
chromatographi
compat
mass
spectrometri
overal
variou
experiment
method
includ
phosphospecif
antibodi
mass
spectrometri
necessari
rigor
identif
vivo
viral
cellular
protein
phosphoryl
nucleosid
class
small
molecul
includ
drug
nucleotid
precursor
dna
rna
nucleosid
frequent
contain
phosphorylat
hydroxyl
group
typic
phosphoryl
requir
nucleic
acid
synthesi
blockag
synthesi
activ
nucleosid
analogu
drug
mani
herpesvirus
includ
hsv
strain
varicella
zoster
viru
contain
thymidin
kinas
capabl
phosphoryl
nucleosid
analogu
hcmv
encod
viral
thymidin
kinas
viral
kinas
capabl
phosphoryl
nucleosid
analogu
number
nucleosid
analogu
develop
exploit
viral
kinas
therapeut
purpos
ganciclovir
acyclovir
guanosin
analogu
current
use
treatment
herpesvirus
nucleosid
analogu
first
phosphoryl
viral
kinas
subsequ
phosphoryl
cellular
kinas
form
nucleosid
triphosph
nucleosid
triphosph
incorpor
viral
dna
polymeras
nascent
dna
strand
lead
chain
termin
case
acyclovir
internucleotid
incorpor
case
ganciclovir
overal
nucleosid
analogu
inhibit
viral
dna
replic
thu
decreas
herpesvir
replic
cidofovir
anoth
nucleosid
analogu
inhibit
herpesvir
replic
phosphoryl
cellular
kinas
incorpor
viral
dna
termin
dna
chain
differ
nucleosid
analogu
drug
vari
efficaci
inhibit
specif
herpesvirus
exampl
ganciclovir
effect
acyclovir
inhibit
hcmv
replic
increas
accumul
ganciclovir
triphosph
compar
acyclovir
triphosph
cell
mani
drug
use
treatment
viral
infect
use
nucleosid
analogu
patient
lead
develop
resist
mutat
viral
thymidin
kinas
andor
kinas
nucleosid
analogu
substrat
hcmv
reduc
elimin
kinas
abil
phosphoryl
nucleosid
analogu
lead
viral
resist
drug
hand
cidofovir
phosphoryl
viral
kinas
mutat
kinas
affect
cidofovir
efficaci
addit
mutat
dna
polymeras
alter
nucleosid
analogu
inhibit
dna
synthesi
induc
resist
nucleosid
analogu
treatment
wherea
acyclovir
prodrug
well
toler
consider
toxic
ganciclovir
particularli
bone
marrow
suppress
cidofovir
nephrotox
make
strategi
inhibit
maribavir
other
lipid
cidofovir
subject
ongo
research
overal
howev
nucleosid
analogu
requir
viral
cellular
kinas
becom
mainstay
treatment
herpesvir
infect
although
nucleosid
analogu
tradit
antivir
turn
specif
benzimidazol
ribosid
maribavir
inhibit
hcmv
viral
kinas
rather
viral
polymeras
mutant
map
phase
ii
studi
show
treatment
efficaci
hiv
patient
well
role
prophylaxi
stem
cell
transplant
patient
phase
iii
studi
unabl
show
superior
maribavir
prophylaxi
strategi
therapi
valganciclovir
ganciclovir
retrospect
problem
studi
design
may
explain
disappoint
result
regardless
inhibit
kinas
remain
avenu
investig
antivir
therapi
poxvir
protein
phosphoryl
number
cellular
tyrosin
kinas
tabl
tyrosin
kinas
phosphoryl
vaccinia
viral
membran
protein
phosphoryl
envelop
virion
induc
actin
tail
format
allow
viral
motil
toward
cell
surfac
tyrosin
kinas
involv
detach
envelop
virion
actin
tail
lead
format
extracellular
envelop
viru
extracellular
envelop
virus
hypothes
involv
viral
dissemin
throughout
infect
organ
effect
cellular
tyrosin
kinas
viral
motil
releas
conserv
variola
monkeypox
virus
well
import
tyrosin
kinas
poxviru
replic
ongo
studi
examin
abil
tyrosin
kinas
inhibitor
serv
treatment
poxvirus
sinc
tyrosin
kinas
inhibitor
gleevec
imatinib
mesyl
first
transform
treatment
chronic
myeloid
leukemia
decad
ago
number
tyrosin
kinas
inhibitor
use
therapi
cancer
cell
infect
poxvirus
vaccinia
variola
monkeypox
gleevec
inhibit
abl
famili
tyrosin
kinas
reduc
poxvir
extracellular
envelop
viru
releas
prophylact
treatment
mice
reduc
viral
load
ovari
day
increas
surviv
among
lethal
challeng
mice
therapeut
treatment
gleevec
h
likewis
increas
surviv
among
mice
although
efficaci
decreas
time
infect
treatment
increas
addit
treatment
gleevec
reduc
viral
dissemin
distal
tissu
mice
infect
intranas
vaccinia
sprycel
inhibitor
kinas
strongli
inhibit
extracellular
envelop
viru
format
releas
cell
cultur
howev
unlik
gleevec
sprycel
dasatinib
minim
effect
mous
surviv
vivo
viral
load
possibl
effect
spleen
andor
bone
marrow
caus
drug
src
inhibit
poxvirus
encod
epiderm
growth
factor
egf
growth
factor
interact
egf
receptor
egfr
viral
encod
growth
factor
activ
tyrosin
kinas
activ
induc
downstream
signal
cascad
promot
viral
replic
small
molecul
inhibitor
tyrosin
kinas
activ
iressa
gefitinib
decreas
phosphoryl
activ
iressa
effect
activ
downstream
effect
correl
decreas
vitro
vaccinia
viral
infect
viral
spread
indic
decreas
vaccinia
plaqu
number
size
iressa
approv
efficaci
inhibit
poxvir
replic
yet
demonstr
mammalian
system
inhibitor
kinas
activ
yet
fda
approv
studi
mice
inhibitor
includ
famili
includ
small
molecul
inhibitor
canertinib
canertinib
reduc
variola
vaccinia
extracellular
envelop
viru
format
andor
releas
cell
cultur
vivo
prophylact
treatment
canertinib
show
modest
effect
increas
mous
surviv
reduc
viral
titer
lung
augment
immun
respons
increas
level
combin
canertinib
chemotherapi
immunotherapi
vaccinia
protein
antibodi
treatment
enhanc
effect
especi
treatment
adsorpt
rabbit
poxviru
myxoma
viru
induc
tyrosin
phosphoryl
cellular
receptor
tyrosin
kinas
reduc
tyrosin
phosphoryl
also
associ
decreas
myxoma
viral
replic
suggest
role
poxvir
replic
tyrosin
kinas
well
peptid
mimet
suppressor
cytokin
signal
inhibit
tyrosin
kinas
peptid
significantli
decreas
phosphoryl
downstream
stat
decreas
vaccinia
viru
replic
cell
cultur
vivo
mimet
peptid
tkip
improv
surviv
among
vaccinia
lethal
infect
mice
administ
prophylact
therapeut
distal
tissu
detect
level
viru
day
intranas
infect
mice
tyrosin
kinas
inhibitor
fda
approv
use
cancer
sever
year
therefor
consider
knowledg
accumul
side
effect
profil
risk
benefit
ration
specif
cancer
exampl
sinc
gleevec
fda
approv
form
tyrosin
kinas
inhibit
remain
mainstay
treatment
chronic
myeloid
leukemia
cancer
indic
iressa
controversi
first
fda
approv
salvag
use
cell
lung
cancer
decis
use
tyrosin
kinas
inhibitor
epiderm
growth
factor
receptor
oppos
chemotherapi
distinct
mode
action
efficaci
cost
toxic
iressa
gener
mild
toxic
effect
acn
dermatolog
condit
respond
treatment
interrupt
efficaci
tyrosin
kinas
inhibitor
poxvirus
anim
model
promis
yet
use
patient
knowledg
treatment
includ
cidofovir
poxvirus
current
limit
may
toxic
effect
thu
potenti
develop
tyrosin
kinas
inhibitor
safe
effect
prophylact
therapeut
treatment
poxvirus
point
interest
current
research
one
use
kinas
inhibitor
alreadi
becom
realiti
treatment
viral
infect
patient
includ
treatment
kaposi
sarcoma
ks
sirolimuseverolimu
rapamycin
sirolimu
everolimu
serinethreonin
kinas
inhibitor
cellular
mtor
kinas
herpesviru
also
known
human
herpesviru
caus
neoplast
hypervascular
lesion
immunocompromis
rare
immunocompet
patient
infect
viru
particularli
common
patient
hiv
rate
gener
popul
solid
organ
bone
marrow
transplant
patient
rate
gener
popul
although
singl
approach
treat
ks
becom
univers
accept
common
practic
transplant
patient
develop
ks
limit
use
immunosuppress
lead
resolut
diseas
complet
stop
immunosuppress
though
left
patient
vulner
graft
reject
two
group
report
seri
patient
well
accompani
anim
tissu
data
suggest
switch
solid
organ
transplant
patient
immunosuppress
cocktail
regimen
one
includ
sirolimu
rapamycin
result
complet
resolut
ks
lesion
subsequ
report
review
stallon
et
al
suggest
mtor
inhibitor
everolimu
effect
mtor
inhibit
play
import
role
resolut
ks
although
degre
mechan
less
immunosuppress
versu
blockag
phosphoryl
event
remain
subject
research
mechanist
data
includ
report
though
show
endotheli
cell
ks
tumor
upregul
vascular
endotheli
growth
factor
vegf
receptor
mtor
inhibitor
block
interact
vegf
limit
cellular
respons
vegf
array
kinas
inhibitor
becom
approv
cancer
therapi
patient
viral
associ
cancer
hepatocellular
cancer
well
cervic
head
neck
cancer
may
receiv
kinas
therapi
basi
cancer
diagnosi
kinas
inhibitor
cost
toxic
issu
must
taken
account
research
util
antivir
undertaken
nevertheless
efficaci
sirolimu
everolimu
demonstr
kinas
inhibitor
could
role
play
combat
viral
infect
wide
varieti
cellular
viral
kinas
impact
viral
replic
kinas
phosphoryl
viral
protein
substrat
small
molecul
promot
initi
continu
cellular
signal
pathway
mani
medic
relev
virus
evolv
exploit
activ
kinas
promot
viral
replic
thu
cellular
viral
kinas
may
serv
target
prophylact
therapeut
treatment
viral
infect
compound
previous
success
treat
variou
cancer
research
ongo
determin
drug
efficaci
treat
viral
infect
author
compet
interest
